Drugs / Intravenous route of active treatment
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00809146 Comparator | Jun 2009 → Jan 2011 | — | Robert Silbergleit | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intravenous route of active treatment | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00809146 ↗ |
| Route | Intravenous | “IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above” NCT00809146 ↗ |